Search Results
Your search for ,had matches 18600 pages
Showing 6601 - 6650William Dameshek, MD, Helped Take Hematology From a Minor Medical Discipline to a Major Scientific Field
Although William Dameshek, MD, is renowned for his work in hematology, especially in advancing the understanding of myeloproliferative disorders and their interrelatedness, his early interest in medicine was instead focused on such diverse diseases as hyperthyroidism and typhus fever. Born on May...
Darolutamide Improves Overall Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial
As reported in The New England Journal of Medicine by Karim Fizazi, MD, of the Institut Gustave Roussy, University of Paris-Saclay, Villejuif, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic...
Dasatinib/Blinatumomab Produces High Rates of Molecular Response and Survival in Philadelphia Chromosome–Positive ALL
In an Italian phase II trial (GIMEMA LAL2116) reported in The New England Journal of Medicine, Robin Foà, MD, of Sapienza University of Rome, and colleagues, found that first-line induction and consolidation treatment with dasatinib and blinatumomab produced a high rates of molecular response as...
Ixazomib Maintenance in Patients With Newly Diagnosed Multiple Myeloma Who Did Not Receive ASCT
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, Greece, and colleagues, the phase III TOURMALINE-MM4 trial has shown that postinduction maintenance with ixazomib prolonged progression-free survival vs placebo in...
Final Efficacy Results From ExteNET Trial of Neratinib in Subgroup of Patients With HR-Positive, HER2-Positive Early Breast Cancer
In an analysis from the phase III ExteNET trial reported in Clinical Breast Cancer, Arlene Chan, MD, of the Breast Cancer Research Centre of Western Australia and Curtin University, Perth, and colleagues, found significant improvements in efficacy outcomes with administration of neratinib vs...
First-Line Atezolizumab Improves Overall Survival vs Chemotherapy in Certain Patients With Metastatic NSCLC
As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, of Yale School of Medicine, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in metastatic non–small cell lung...
Addition of Abemaciclib to Endocrine Therapy Improves Invasive Disease–Free Survival in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, and colleagues, an interim analysis in the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive...
Update on Multiple Myeloma: Highlights From NCCN Virtual Congress on Hematologic Malignancies
New diagnostic criteria and modern imaging techniques, a wealth of new therapeutics, and an update on current thinking as to when to treat patients with smoldering myeloma were highlighted during the National Comprehensive Cancer Network (NCCN) 2020 Virtual Congress: Hematologic Malignancies™....
Expert Point of View: Ajay K. Nooka, MD, MPH
“Both KarMMa and CARTITUDE-1 trials presented during the ASCO20 Virtual Scientific Program showed exceptional results, not only in obtaining higher responses in the majority of patients but also in attaining high-quality responses,” said Ajay K. Nooka, MD, MPH, Associate Professor, Department of...
Support Builds for Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell...
Expert Point of View: Fatima Cardoso, MD
The SOLAR-1 invited discussant, Fatima Cardoso, MD, Director of the Breast Unit at the Champalimaud Clinical Center in Lisbon and Chair of the ABC Global Alliance, commented: “The overall survival results, though numerically different by almost 8 months, unfortunately do not reach statistical...
Final Analysis of SOLAR-1: 8-Month Survival Benefit Misses Statistical Significance for Alpelisib
The statistically significant benefit of alpelisib in reducing disease progression, as reported at the European Society for Medical Oncology (ESMO) Congress 2 years ago, did not translate into a significant improvement in overall survival, although a numerical 8-month gain was observed in the final ...
Growing Interest in Antiandrogens to Treat Male Breast Cancer
“There has been a lot of interest in the development of new antiandrogens” for clinical use in patients with breast cancer,” Anthony D. Elias, MD, reported in an update on male breast cancer at the 2020 Lynn Sage Breast Cancer Symposium, sponsored by the Robert H. Lurie Comprehensive Cancer Center...
Pembrolizumab in Adult and Pediatric Classical Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 14, 2020, the approval of pembrolizumab was...
Mode of Detection of High-Risk Breast Cancer Linked to Prognosis
Breast cancers detected between mammographic screenings carry a worse prognosis than those detected at the time of screening, even when tumor biology is similar, according to research presented at the 12th European Breast Cancer Conference (EBCC 12), which was held virtually this year.1 The 8-year...
Expert Point of View: Keerthi Gogineni, MD, MSHP
Keerthi Gogineni, MD, MSHP, Assistant Professor of Hematology and a medical oncologist at Emory University School of Medicine, Atlanta, commented on the long-term follow-up of the MINDACT trial presented at the 12th European Breast Cancer Conference. She noted that, for patients with early-stage...
MINDACT at 8.7 Years: Primary Findings Confirmed
Long-term analysis of the phase III MINDACT trial, with a median follow-up of 8.7 years, confirmed that the 70-gene signature MammaPrint assay can identify which patients with breast cancer can safely forgo adjuvant chemotherapy, reported Emiel Rutgers, MD, PhD, FRCS, a surgical oncologist at the...
Hairy Cell Leukemia Foundation and Leukemia & Lymphoma Society Join Forces
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) recently announced they are teaming up to support a research grants program of up to $10 million over 5 years. Their goal is to build a more comprehensive understanding of hairy cell leukemia, develop better...
Can Antihypertensives Improve Outcomes With Immunotherapy?
Angiotensin receptor blockers, commonly used to treat hypertension, may improve outcomes in patients treated with anti–PD-1/L1 agents, according to an observational study of almost 600 patients reported at the virtual 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1 The...
KRAS Inhibitor Adagrasib Shows Activity in Non–Small Cell Lung Cancer
Another novel oral KRAS inhibitor—adagrasib (MRTX849)—has shown promise in early clinical trials, according to investigators of the KRYSTAL-1 study who reported findings at the virtual 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.1,2 The conference is jointly provided...
Use of Pembrolizumab in Advanced Pleural Mesothelioma: Results From KEYNOTE-158
The largest single-arm trial evaluating pembrolizumab in relapsed malignant pleural mesothelioma has demonstrated an “impressive” duration of response, according to a presentation during the virtual edition of the International Association for the Study of Lung Cancer (IASLC) 2020 North America...
Stereotactic Radiosurgery May Delay Cognitive Deterioration vs Whole-Brain Radiotherapy for Multiple Brain Metastases
Stereotactic radiosurgery appears to be a new standard of care for patients with four or more nonmelanoma brain metastases, perhaps replacing whole-brain radiotherapy in this setting, according to a potentially practice-changing phase III study presented at the 2020 American Society for Radiation...
Expert Point of View: Kristin J. Redmond, MD, MPH
Formal discussant of the CCTG SC.24/TROG 17.06 trial, Kristin J. Redmond, MD, MPH, of The Johns Hopkins University School of Medicine, Baltimore, expressed confidence in the findings of Dr. Sahgal’s study. “We now have level 1 data to support a stereotactic body radiation therapy (SBRT) dose of 24 ...
Management of Painful Spinal Metastases: SBRT vs Conventional Radiotherapy
Stereotactic body radiation therapy (SBRT) was superior to conventional radiation therapy in reducing pain from spinal metastases in a phase II/III study reported at the virtual edition of the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 More than twice as many patients...
Analysis Seeks to Identify Characteristics of 'Exceptional Responders' to Cancer Therapy
In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers identified molecular changes in the patients’ tumors that may explain some of these outcomes. The results, published by Wheeler et al in Cancer Cell, demonstrated that genomic characterizations ...
Phase III GEMSTONE-302 Trial Finds CS1001 Plus Platinum Chemotherapy Prolongs Progression-Free Survival in NSCLC
The addition of CS1001, an anti–PD-L1 monoclonal antibody, to platinum-based chemotherapy significantly prolonged progression-free survival vs chemotherapy in treatment-naive patients with advanced non–small cell lung cancer (NSCLC), according to phase III findings presented by Zhou et al at the...
Image-Guided IMRT Reduces GI Toxicity Without Compromising Pelvic Recurrence in Intermediate- to High-Risk Cervical Cancer
Post-hysterectomy image-guided intensity-modulated radiation therapy (IMRT) was superior to three-dimensional conformal radiation therapy (3D-CRT) in reducing the side effects of pelvic radiation while achieving similar tumor control in women with high-risk cervical cancer, according to the final...
Phase II Study Investigates Efficacy of Anlotinib in Radioiodine-Refractory Differentiated Thyroid Cancer
Patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma demonstrated a statistically significant progression-free survival benefit when treated with anlotinib, a novel tyrosine kinase inhibitor, vs placebo, as well as higher response rates, according to...
ESMO Asia 2020: First-Line Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma
Sintilimab, an anti–PD-1 antibody, in combination with a bevacizumab biosimilar as first-line therapy significantly improved survival compared to sorafenib in patients with advanced hepatocellular carcinoma, according to findings presented by Ren et al at the ESMO Asia Virtual Congress 2020...
Nivolumab Plus Ipilimumab in First-Line NSCLC: Two New Indications, Many More Questions
In May 2020, the combination of nivolumab and ipilimumab was approved by the U.S. Food and Drug Administration (FDA) for two separate indications in the first-line setting of advanced non–small cell lung cancer (NSCLC). One was in metastatic NSCLC with tumors that have PD-L1 expression ≥ 1% with...
Fluciclovine PET Imaging Benefits Radiotherapy Treatment Planning Compared With Conventional Imaging in Prostate Cancer
The addition of the radiotracer fluciclovine to positron-emission tomography (PET) imaging for radiotherapy treatment planning led to superior failure-free survival compared with conventional imaging in men with prostate cancer who had undergone radical prostatectomy and were experiencing biologic ...
Reconstruction Implant Surface Texture and Risk of Breast Cancer Recurrence
In a Korean single-institution cohort study reported in JAMA Surgery, Lee et al found that the use of textured surface implants in breast reconstruction following mastectomy for breast cancer was associated with poorer disease-free survival. Study Details The study involved data from 650 women...
Adoption of Hypofractionated Radiation Therapy After Change in Prostate Cancer Clinical Pathway
In a study reported in JCO Oncology Practice, Schad et al found that modifying the prostate cancer clinical pathway in an integrated oncology network to designate moderately hypofractionated external-beam radiotherapy (mHF-EBRT) as the recommended curative EBRT monotherapy in low- and...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet by Grosicki et al, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated patients with multiple myeloma. Study Details...
Expert Point of View: Alejandro Berlin, MD, MSc
Discussant of the abstract, Alejandro Berlin, MD, MSc, Assistant Professor at the Princess Margaret Cancer Centre, Toronto, called the study “thought-provoking” and applauded the data-sharing approach to answer a clinically relevant question. According to Dr. Berlin, this work resurfaces the...
Adjuvant vs Neoadjuvant Androgen-Deprivation Therapy With Radiotherapy for Prostate Cancer
Sequencing of androgen-deprivation therapy with radiotherapy has a significant impact on long-term outcomes in localized prostate cancer, according to data presented during the virtual edition of the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Pooled individual patient...
ESMO Asia 2020: Futibatinib for Patients With Refractory Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements
Clinical benefit was provided by the FGFR1–4 inhibitor futibatinib in patients with refractory intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements, including those enrolled in Asian countries. These findings were presented by Furuse et al at the ESMO Asia Virtual...
ESMO Asia 2020: Novel PD-L1 Antibody Shows Activity in Advanced MSI-H/dMMR Tumors
Envafolimab (also known as KN035), a novel PD-L1 antibody, demonstrated antitumor activity and was safe in patients with diverse, advanced microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) tumors, according to findings presented by Shen et al at the ESMO Asia Virtual Congress...
ESMO Asia 2020: Early Detection and Localization of Cancer Using a Blood-Based Assay
The ELSA-seq assay was able to detect diverse cancer types at early stages with high specificity and was able to provide information regarding the tissue of origin, according to findings presented by Gao et al at the ESMO Asia Virtual Congress 2020 (Abstract LBA3). Qiang Gao, MD, PhD, of the Liver...
ESMO Asia 2020: Baseline Characteristics of Asian Patients Enrolled in the monarchE Trial
A comparison of baseline characteristics in patients with hormone receptor (HR)-positive, HER2-negative early breast cancer revealed that a higher proportion of patients enrolled from Asia had risk factors for disease recurrence than those enrolled from non-Asian countries, reported Jiang et al at...
First-Line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
As reported in The New England Journal of Medicine by Alice T. Shaw, MD, PhD, and colleagues, an interim analysis of the phase III CROWN trial has shown that first-line lorlatinib significantly improved progression-free survival and intracranial response rate vs crizotinib in patients with advanced ...
Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer
In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....
4-Year Findings From MURANO Trial: Venetoclax Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
As reported in the Journal of Clinical Oncology by Arnon P. Kater, MD, PhD, of Amsterdam University Medical Centers, and colleagues,1 the 4-year progression-free and overall survival rates were significantly higher with venetoclax plus rituximab vs bendamustine plus rituximab in the phase III...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the treatment of patients with chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on...
Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of either...
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, of the Division of Hematology, Mayo Clinic, Rochester, and colleagues,1 the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus...
Expert Point of View: Ajay K. Nooka, MD, MPH
“Both KarMMa and CARTITUDE-1 trials presented during the ASCO20 Virtual Scientific Program showed exceptional results, not only in obtaining higher responses in the majority of patients but also in attaining high-quality responses,” said Ajay K. Nooka, MD, MPH, Associate Professor, Department of...
Support Builds for Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma
Based on early results in clinical trials, interest in the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma has been high, especially for products targeting B-cell maturation antigen (BCMA). During the ASCO20 Virtual Scientific Program, further support for CAR T-cell...
Responses Achieved With Belantamab Mafodotin in Relapsed or Refractory Myeloma
The antibody-drug conjugate belantamab mafodotin yielded responses as a single agent and in combination with bortezomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma, according to two reports from the DREAMM team at the ASCO20 Virtual Scientific Program.1,2 In the...
Novel Treatment Approaches on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase modulators (CELMoDs), antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, FASCO, Director of the Jerome Lipper...
